Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Tooru Shimosegawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1255-5444; OpenAlex author ID A5029930183, A5110152779. Sources: OpenAlex.

Their work

Papers
40 (first author 3, last author 27)
Trials
0
Grants
0
Labs led
1
Collaborators
123
Papers, trials and grants by year

2011: 2 papers · 2012: 7 papers · 2013: 7 papers · 2014: 6 papers · 2015: 6 papers · 2016: 2 papers · 2017: 5 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 40

  1. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  2. Impact of a board certification system and implementation of clinical practice guidelines for pancreatic cancer on mortality of pancreaticoduodenectomy. Co-author DOI 10.1007/s00595-020-02017-3↗
  3. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  4. Exosomes derived from pancreatic cancer cells induce activation and profibrogenic activities in pancreatic stellate cells. Last author DOI 10.1016/j.bbrc.2017.10.141↗
  5. Multicenter study of early pancreatic cancer in Japan. Last author DOI 10.1016/j.pan.2017.11.007↗
  6. Kindlin-2 in pancreatic stellate cells promotes the progression of pancreatic cancer. Last author DOI 10.1016/j.canlet.2017.01.008↗
  7. Exosomes Derived From Pancreatic Stellate Cells: MicroRNA Signature and Effects on Pancreatic Cancer Cells. Last author DOI 10.1097/mpa.0000000000000722↗
  8. Plasma Kallikrein-Dependent Transforming Growth Factor-β Activation in Patients With Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000736↗
  9. Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000000816↗
  10. Familial pancreatic cancer: Concept, management and issues. Last author DOI 10.3748/wjg.v23.i6.935↗
  11. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Last author DOI 10.1097/mpa.0000000000000636↗
  12. [A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer wi… Co-author PMID 28133191↗
  13. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00535-014-0997-0↗
  14. Pancreatic stellate cells: A dynamic player of the intercellular communication in pancreatic cancer. First author DOI 10.1016/j.clinre.2015.05.018↗
  15. [Chronic pancreatitis is a risk factor of pancreatic cancer]. Last author DOI 10.11405/nisshoshi.112.1464↗
  16. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2743↗
  17. [Desmoplastic reaction in pancreatic cancer]. Last author PMID 25856980↗
  18. [Pancreatic cancer stem cell]. Last author PMID 25985641↗
  19. Inflammation and pancreatic cancer: disease promoter and new therapeutic target. Last author DOI 10.1007/s00535-013-0915-x↗
  20. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗
  21. MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Last author DOI 10.1016/j.cellsig.2013.11.003↗
  22. CUB-domain containing protein 1 represses the epithelial phenotype of pancreatic cancer cells. Last author DOI 10.1016/j.yexcr.2013.12.019↗
  23. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  24. The zinc transporter LIV-1 is a novel regulator of stemness in pancreatic cancer cells. Last author DOI 10.3109/00365521.2013.865075↗
  25. miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. Last author DOI 10.1002/jcp.24280↗
  26. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. Last author DOI 10.1007/s00534-013-0611-5↗
  27. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Last author DOI 10.1016/j.bbrc.2013.06.097↗
  28. Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis. Last author DOI 10.1016/j.surg.2012.08.005↗
  29. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Last author DOI 10.3109/00365521.2013.777776↗
  30. Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Last author DOI 10.3389/fphys.2013.00318↗
  31. Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Last author DOI 10.3389/fphys.2013.00331↗
  32. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. Last author DOI 10.1002/jcp.22781↗
  33. Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2012.04.014↗
  34. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Last author DOI 10.1158/1541-7786.mcr-11-0272↗
  35. [Discussion meeting on is it possible to detect pancreatic cancer in early stage?]. Co-author DOI 10.2169/naika.101.120↗
  36. [Pancreatic tumor: progress in diagnosis and treatment. Topics: I. Pancreatic carcinoma: 2. Pathogenesis and pathobiology in pancreatic cancer.--The molecular … First author DOI 10.2169/naika.101.7↗
  37. Regulators of epithelial mesenchymal transition in pancreatic cancer. Last author DOI 10.3389/fphys.2012.00254↗
  38. MSX2 in pancreatic tumor development and its clinical application for the diagnosis of pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fphys.2012.00430↗
  39. The prognosis of patients with pancreatic cancer is extremely poor. Preface. Last author DOI 10.1159/000323476↗
  40. Biomarkers of pancreatic cancer. First author DOI 10.1159/000323479↗

Closest collaborators

The 25 strongest of 123 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Masamune · 25 shared papers, 2012–2026 · strength 1.66
  2. Shin Hamada · 25 shared papers, 2011–2026 · strength 1.63
  3. Michiaki Unno · 6 shared papers, 2013–2026 · strength 0.54
  4. Kennichi Satoh · 11 shared papers, 2012–2015 · strength 0.52
  5. Masamichi Mizuma · 5 shared papers, 2016–2026 · strength 0.49
  6. Tetsuya Takikawa · 6 shared papers, 2012–2018 · strength 0.37
  7. Shinichi Egawa · 4 shared papers, 2013–2026 · strength 0.34
  8. Kazuhiro Kikuta · 7 shared papers, 2012–2017 · strength 0.31
  9. Kazuichi Okazaki · 2 shared papers, 2017–2026 · strength 0.30
  10. Takao Itoi · 3 shared papers, 2014–2026 · strength 0.30
  11. Naoki Yoshida · 4 shared papers, 2013–2018 · strength 0.30
  12. Sohei Satoi · 2 shared papers, 2016–2026 · strength 0.28
  13. Keiji Hanada · 5 shared papers, 2012–2018 · strength 0.25
  14. Kohei Nakata · 1 shared paper, 2026 · strength 0.23
  15. Ichiro Yasuda · 1 shared paper, 2026 · strength 0.23
  16. Yoshifumi Takeyama · 1 shared paper, 2026 · strength 0.23
  17. Manabu Kawai · 1 shared paper, 2026 · strength 0.23
  18. Ken Shirabe · 1 shared paper, 2026 · strength 0.23
  19. Atsushi Kanno · 6 shared papers, 2012–2018 · strength 0.23
  20. Shin Miura · 4 shared papers, 2013–2014 · strength 0.18
  21. Kyoichi Takaori · 3 shared papers, 2013–2020 · strength 0.16
  22. Fuyuhiko Motoi · 3 shared papers, 2013–2017 · strength 0.15
  23. Junji Furuse · 3 shared papers, 2014–2017 · strength 0.15
  24. Toru Furukawa · 3 shared papers, 2013–2018 · strength 0.14
  25. Jun Unno · 3 shared papers, 2012–2014 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.